Tradestie Institutional Equity Comparison Engine

RNEM vs BMED โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMED Overall Edge

BMED Captures Institutional Edge (2โ€“0 Pillars ยท 2โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to iShares Health Innovation Active ETF (BMED) driven by superior Momentum & Technical, Options & Structure. Fundamentally, RNEM trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BMED at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, RNEM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BMED sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
RNEM N/M vs BMED N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner BMED
1Y +3.0% vs +26.0% ยท 52W Pos 81% vs 85%
Options & Structure Winner BMED
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (100th %ile IV)
RNEM US Equity
RNEM
Institutional Equity
$56.71
+0.19% 1D
Market Cap N/A
1M Return -0.38%
1Y Return +2.99%
Forward P/E N/M
Unified AI Score
50.1 / 100 HOLD
Tech 46.0 Fund 47.0 Flow 50.0 Mom 56.3
BMED NYSE Arca
iShares Health Innovation Active ETF
Institutional Equity
$35.85
-1.28% 1D
Market Cap N/A
1M Return +3.76%
1Y Return +26.0%
Forward P/E N/M
Unified AI Score
51.8 / 100 HOLD
Tech 44.0 Fund 44.0 Flow 50.0 Mom 41.6

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RNEM +2.99% BMED +26.0% Spread: +23.72 pp (BMED Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RNEM TTM Op. Margin: N/A BMED TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RNEM vs BMED. Trailing 12-month operating profitability (RNEM N/A vs BMED N/A) and valuation multiples (RNEM N/M vs BMED N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RNEM (1) vs BMED (2)
Institutional Metric RNEM BMED Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 81% ($47โ€“$59) 85% ($27โ€“$37) Stronger Trend BMED
Beta / 30D Volatility Risk Regime 0.61ฮฒ ยท 13% Vol 0.61ฮฒ ยท 24% Vol Lower Realized Risk RNEM
Unified Institutional Score Composite Signal 50.1 / 100 (HOLD) 51.8 / 100 (HOLD) Higher Composite BMED

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RNEM vs BMED Buy Guide
RNEM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RNEM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BMED UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live BMED Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RNEM nor BMED registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.